Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
TSHA Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TSHA Stock 12 Month Forecast
Average Price Target
$6.94
▲(166.92%Upside)
| Highest Price Target$9.00 | Average Price Target$6.94 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$2.5
Hold
-3.85%
Downside
Reiterated
05/16/25
The overall stock score reflects a balance between financial challenges and positive technical and earnings call indicators. While financial performance is a significant concern, the stock's upward momentum and promising clinical developments provide some optimism. The lack of earnings and negative valuation metrics weigh on the score, but the potential for regulatory advancement and improved cash flow stability are key positives.
Truist Financial
―
Buy
―
Reiterated
05/16/25
Citizens JMP
$5
Buy
92.31%
Upside
Reiterated
05/16/25
Wells Fargo
$7.5
Buy
188.46%
Upside
Reiterated
05/16/25
Chardan Capital
$7
Buy
169.23%
Upside
Reiterated
05/15/25
Canaccord Genuity
$8→$9
Buy
246.15%
Upside
Reiterated
05/15/25
BMO Capital
$5
Buy
92.31%
Upside
Reiterated
05/15/25
Robert W. Baird
$7
Buy
169.23%
Upside
Reiterated
05/15/25
Baird reiterates Outperform Rating on Taysha Gene Therapies (TSHA); Encouraged by FDA InteractionsBaird analyst Jack Allen reiterated an Outperform rating and $7.00 price target on Taysha Gene Therapies (NASDAQ: TSHA) saying they are incrementally positive on regulatory update disclosed concurrent with earnings.
Needham
$6
Buy
130.77%
Upside
Reiterated
05/15/25
Piper Sandler
$9
Buy
246.15%
Upside
Initiated
05/01/25
Cantor Fitzgerald
$7
Buy
169.23%
Upside
Reiterated
04/28/25
Jefferies
$8
Buy
207.69%
Upside
Reiterated
08/12/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$2.5
Hold
-3.85%
Downside
Reiterated
05/16/25
The overall stock score reflects a balance between financial challenges and positive technical and earnings call indicators. While financial performance is a significant concern, the stock's upward momentum and promising clinical developments provide some optimism. The lack of earnings and negative valuation metrics weigh on the score, but the potential for regulatory advancement and improved cash flow stability are key positives.
Truist Financial
―
Buy
―
Reiterated
05/16/25
Citizens JMP
$5
Buy
92.31%
Upside
Reiterated
05/16/25
Wells Fargo
$7.5
Buy
188.46%
Upside
Reiterated
05/16/25
Chardan Capital
$7
Buy
169.23%
Upside
Reiterated
05/15/25
Canaccord Genuity
$8→$9
Buy
246.15%
Upside
Reiterated
05/15/25
BMO Capital
$5
Buy
92.31%
Upside
Reiterated
05/15/25
Robert W. Baird
$7
Buy
169.23%
Upside
Reiterated
05/15/25
Baird reiterates Outperform Rating on Taysha Gene Therapies (TSHA); Encouraged by FDA InteractionsBaird analyst Jack Allen reiterated an Outperform rating and $7.00 price target on Taysha Gene Therapies (NASDAQ: TSHA) saying they are incrementally positive on regulatory update disclosed concurrent with earnings.
Needham
$6
Buy
130.77%
Upside
Reiterated
05/15/25
Piper Sandler
$9
Buy
246.15%
Upside
Initiated
05/01/25
Cantor Fitzgerald
$7
Buy
169.23%
Upside
Reiterated
04/28/25
Jefferies
$8
Buy
207.69%
Upside
Reiterated
08/12/24
Best Analysts Covering Taysha Gene Therapies
1 Month
xxx
Success Rate
11/22 ratings generated profit
Average Return
+3.01%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.01% per trade.
3 Months
xxx
Success Rate
10/29 ratings generated profit
Average Return
-8.18%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 34.48% of your transactions generating a profit, with an average return of -8.18% per trade.
1 Year
2 Years
xxx
Success Rate
9/17 ratings generated profit
Average Return
+23.38%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.94% of your transactions generating a profit, with an average return of +23.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TSHA Analyst Recommendation Trends
Rating
Nov 24
Jan 25
Feb 25
Apr 25
May 25
Strong Buy
15
16
17
9
16
Buy
2
1
2
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
17
19
10
18
Each month's total comprises the sum of three months' worth of ratings.
TSHA Financial Forecast
TSHA Stock Forecast FAQ
What is TSHA’s average 12-month price target, according to analysts?
Based on analyst ratings, Taysha Gene Therapies’s 12-month average price target is 6.94.
What is TSHA’s upside potential, based on the analysts’ average price target?
Taysha Gene Therapies has 166.92% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TSHA a Buy, Sell or Hold?
Taysha Gene Therapies has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Taysha Gene Therapies’s price target?
The average price target for Taysha Gene Therapies is 6.94. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $5.00. The average price target represents 166.92% Increase from the current price of $2.6.
The highest analyst price target is $9.00 ,the lowest forecast is $5.00. The average price target represents 166.92% Increase from the current price of $2.6.
What do analysts say about Taysha Gene Therapies?
Taysha Gene Therapies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of TSHA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.